Abstract
ABSTRACTTo the best of our knowledge, non-vitamin K antagonist oral anticoagulants (NOACs), or direct oral anticoagulants, have not been tested in randomized trials conducted in patients with atrial fibrillation (AF), affected by malignant disease. However, their use in patients with cancer is increasing, while real-life evidence for their effectiveness and safety in this vulnerable subset of patients is growing. The challenges of the use of NOACs in cancer patients with AF and current expert opinion on this subject have been summarized in this review article.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
